Can Doximity's New AI Suite Drive the Growth It Needs?
DOCS reports stronger Q1 results and is betting on its new AI suite -- Scribe, GPT, and Pathway -- to drive its next growth phase.
Doximity ( DOCS ) Stock Sinks As Market Gains: What You Should Know
Doximity (DOCS) closed the most recent trading day at $70.64, moving 3.43% from the previous trading session.
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Congressional Trading Report: Rep. Jonathan Jackson Bought Over $16K In Doximity Stock - Doximity ( NYSE:DOCS ) , ARM Holdings ( NASDAQ:ARM )
An official report on September 23, 2025 reveals Representative Jonathan Jackson's recent purchase of Doximity DOCS stock, valued between $16,002 and $65,000. The transaction took place on August 25, 2025, as per the September filing. At this time, Doximity shares are trading up 1.54% at $75.03.
Do Options Traders Know Something About Doximity Stock We Don't?
Investors need to pay close attention to DOCS stock based on the movements in the options market lately.
Hims & Hers Expands Care Ecosystem via Global and Digital Innovation
HIMS is scaling globally with AI-powered care, new treatments and an $870 million boost to expand its digital ecosystem.
Doximity ( DOCS ) Exceeds Market Returns: Some Facts to Consider
Doximity (DOCS) closed at $73.6 in the latest trading session, marking a +1.28% move from the prior day.
Doximity ( DOCS ) Increases Despite Market Slip: Here's What You Need to Know
Doximity (DOCS) closed at $71.03 in the latest trading session, marking a +1.1% move from the prior day.
What's Driving the Market Sentiment Around Doximity? - Doximity ( NYSE:DOCS )
Doximity's DOCS short interest as a percent of float has risen 7.65% since its last report. According to exchange reported data, there are now 4.70 million shares sold short, which is 3.52% of all regular shares that are available for trading.
Phreesia PHR Q2 2026 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Sept. 4, 2025 at 5 p.m. ETChief Executive Officer - Chaim IndigContinue reading ...
HIMS' Personalized Wellness Platform Expands Preventive Care Access
Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
Deal Dispatch: Performance Food Rejects Offer, Claire's Bankrupt - American Woodmark ( NASDAQ:AMWD ) , Boeing ( NYSE:BA )
Performance Food rejects offer; Bachan's, Hg and Yomeishu explore sales; Lufthansa drops Air Europa bid; NFL sells media to ESPN Skydance Media finally completed its $8-billion acquisition of Paramount Global. Sen. Warren called it a "wink, wink" arrangement.
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
Doximity Analysts Increase Their Forecasts After Strong Q1 Earnings - Doximity ( NYSE:DOCS )
Doximity Inc DOCS reported better-than-expected earnings for the first quarter on Thursday. The company posted quarterly earnings of 36 cents per share which beat the analyst consensus estimate of 30 cents per share.
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday - Blue Gold ( NASDAQ:BGL ) , Astrana Health ( NASDAQ:ASTH )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Friday. Shares of SoundHound AI, Inc. SOUN rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates.
Pinterest To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Friday - Crocs ( NASDAQ:CROX ) , Doximity ( NYSE:DOCS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keefe, Bruyette & Woods raised Block Inc XYZ price target from $80 to $95.
Doximity ( DOCS ) Q1 Revenue Rises 15%
Doximity ( NYSE:DOCS ) , a leading digital platform for medical professionals, released results for Q1 FY2026 on August 7, 2025. The company posted GAAP revenue of $145.9 million, missing analyst expectations of $154.4 million ( GAAP ) by about 5.5%.
Doximity ( DOCS ) Q1 Earnings and Revenues Top Estimates
Doximity (DOCS) delivered earnings and revenue surprises of +16.13% and +4.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers
Pathway's AI-powered clinical reference tool helps doctors answer questions about guidelines, drugs and trials.
Doximity Unusual Options Activity For August 07 - Doximity ( NYSE:DOCS )
Financial giants have made a conspicuous bullish move on Doximity. Our analysis of options history for Doximity DOCS revealed 11 unusual trades. Delving into the details, we found 63% of traders were bullish, while 27% showed bearish tendencies.
Is Doximity Gaining or Losing Market Support? - Doximity ( NYSE:DOCS )
Doximity's DOCS short percent of float has fallen 13.66% since its last report. The company recently reported that it has 4.97 million shares sold short, which is 3.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.02 days to cover ...
Claritev Corporation ( CTEV ) Q2 Earnings and Revenues Surpass Estimates
Claritev Corporation (CTEV) delivered earnings and revenue surprises of +111.90% and +4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. ( HIMS ) Misses Q2 Earnings and Revenue Estimates
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -5.56% and -1.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
These top telehealth stocks look like smart growth plays right now.
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.
Doximity ( DOCS ) Reports Next Week: Wall Street Expects Earnings Growth
Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
OPRX's subscription shift, DAAP platform, and HCP-DTC reach suggest a moat is forming-but is it built to last?
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell ( OMCL Quick QuoteOMCL - ) and Doximity ( DOCS Quick QuoteDOCS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.
Doximity ( DOCS ) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.
UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs
UNH misses Q2 earnings estimates as surging medical costs slash EPS 40%, despite revenue growth and Optum Rx strength.
Universal Health Q2 Earnings Beat on Strong Acute Care Admissions
UHS tops Q2 estimates with EPS up 24% as strong acute care and behavioral admissions drive revenue growth.
ImmunoPrecise Antibodies Ltd. ( IPA ) Reports Q4 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -100.00% and -17.86%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Community Health Q2 Earnings Miss on Declining Patient Days
CYH posts Q2 loss despite revenue beat, as patient days and adjusted admissions decline year over year.
Molina Healthcare Q2 Earnings Miss on Rising Medical Care Costs
MOH's Q2 earnings lag estimates as rising medical care costs offset gains from premiums and rate hikes.
Doximity ( DOCS ) Upgraded to Strong Buy: Here's Why
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Healthy Returns: Researchers move closer to a universal cancer vaccine
University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings season is approaching.
Doximity ( DOCS ) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.
Doximity ( DOCS ) Rises Higher Than Market: Key Facts
Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.
Do Options Traders Know Something About Doximity Stock We Don't?
Investors need to pay close attention to DOCS stock based on the movements in the options market lately.
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - Doximity ( NYSE:DOCS )
SAN DIEGO, July 09, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. DOCS shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.
This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Bloom Energy ( NYSE:BE ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.
How Do Investors Really Feel About Doximity? - Doximity ( NYSE:DOCS )
Doximity's DOCS short percent of float has risen 13.82% since its last report. The company recently reported that it has 5.59 million shares sold short, which is 4.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.65 days to cover their ...
Doximity ( DOCS ) Laps the Stock Market: Here's Why
Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
